December 7, 2020 -- MilliporeSigma is increasing its manufacturing footprint in the U.S. with a $47 million investment in its Danvers, MA, and Jaffrey, NH, biomanufacturing facilities.
The expansions will increase capacity and output in 2021 (MA) and 2022 (NH) and create 700 new manufacturing positions. These sites will supply critical products to customers for the development and manufacturing of therapies, including COVID-19 vaccines.
MilliporeSigma's combined expansions are expected to create nearly 700 new jobs in New Hampshire and Massachusetts. Image courtesy of MilliporeSigma.
The Danvers expansion will add 65,000 sq ft of single-use assembly operations to the existing 120,000-sq-ft facility. This will support MilliporeSigma's Mobius single-use consumables production. The total investment in about $25 million and will add approximately 400 jobs throughout 2021.
The Jaffrey expansion will add 25,000 sq ft to the existing 260,000-sq-ft facility. The additional capacity will include new production lines and equipment and support production of filtration devices and membrane products, namely, Durapore filters, Express filters, and Viresolve products that are used to remove viral contamination during therapeutic production. The total investment in Jaffrey is $22 million and will bring 275 jobs by 2022.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
